All News

At 2022 ASCO, Tanya Dorff, MD, reviewed the use of CAR T cells in the treatment of prostate cancer.

Angela DeMichele, MD, MSCE, discussed how the standard of care can be shifted based on the results of the phase 2 I-SPY2 trial investigating novel neoadjuvant treatment strategies in early breast cancer.

Based on findings from a real-world retrospective analysis, Stacey A. Cohen, MD, discussed the prognostic value of post-surgical minimal residual disease detection in patients with stage I to III colorectal cancer.

Findings from a pooled analysis indicated that a decrease in circulating tumor DNA was associated with improved clinical benefit in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.

Findings from a phase 2 clinical study indicated that neoadjuvant pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab, and pertuzumab demonstrated promising efficacy and safety in the treatment of HER2-positive breast cancer.

Results from the phase 1/2 MajesTEC-1 trial highlighted sustained responses when teclistamab was used to treat patients with relapsed/refractory multiple myeloma who are triple refractory.

Patients with stage IVA to IVB nasopharyngeal carcinoma experienced an improvement in failure-free survival following treatment with paclitaxel, cisplatin, and capecitabine for 2 cycles vs 2 cycles of cisplatin and fluorouracil.

In patients with acute myeloid leukemia receiving venetoclax, tumor lysis syndrome was uncommon; patients at high risk should be admitted for venetoclax dosing ramp-up.

Investigators support individualized approaches and compassionate care to minimize nonmedical opioid use and opioid use disorder in patients with cancer pain.

Hossein Borghaei, DO, MS, discussed where investigators may drive future research following the phase 2 Lung-MAP trial examining pembrolizumab and ramucirumab in previously treated advanced non–small cell lung cancer.

Routine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.

A supplement biologics license and a Type II variation were submitted to the FDA and European Medicines Agency, respectively, for first-line rucaparib in patients with advanced ovarian cancer.

Roy S. Herbst, MD, PhD, considers next steps in the management of patients with non–small cell lung cancer harboring genomic drivers.

Alexander I. Spira, MD, PhD, FACP, details the safety profile of single-agent adagrasib in patients with KRAS G12C–mutated advanced or metastatic non–small cell lung cancer, as well as plans for future research following the phase 1/2 KRYSTAL-1 study.

Mary E.R. O’Brien, MBBS, discussed results of an exploratory analysis of the phase 3 PEARLS/KEYNOTE-091 study examining pembrolizumab in resected non–small cell lung cancer.

“Opportunities to escalate therapies that work well in stage IV into what we consider a more curative setting...are exactly what we need to be looking for.” –Mark A. Socinski, MD

Final data from the phase 2 ATLEP trial showed high response rates with a combination of lenvatinib and pembrolizumab in patients with anaplastic and poorly differentiated thyroid cancer.

Findings from the phase 2 KEYNOTE-B61 trial demonstrated promising efficacy with a combination of pembrolizumab and lenvatinib in the frontline treatment of non–clear cell renal cell carcinoma.

Data from the phase 1 METEOR-1 trial showed modest efficacy with GSK3326595, a PRMT5 inhibitor, in patients with advanced solid tumors.

Howard S. Hochster, MD, considers drug price negotiation in this month's Letter to the Readers.

A pooled exploratory analysis of phase 3 trials found statistically significant progression-free survival and overall survival benefits with ribociclib/endocrine therapy for patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

Findings from the phase 1b/2 KRYSTAL-1 trial showed encouraging responses with adagrasib in patients with advanced KRAS G12C-mutant colorectal cancer.

Treatment with fam-trastuzumab deruxtecan-nxki yielded promising patient-reported outcomes in patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to Naoto Ueno, MD, PhD.

Data from the phase 2 LITESPARK-003 trial demonstrated antitumor activity and a well-tolerated safety profile with belzutifan plus cabozantinib in patients with clear cell renal cell carcinoma.

Health-related quality of life data from the phase 2 KEYNOTE-522 trial did not show ill effects of pembrolizumab vs placebo in patients with triple-negative breast cancer.

Results from the LITESPARK-003 trial showed continued antitumor activity after 2 years with belzutifan plus cabozantinib.

Findings from the phase 3 PRESTO trial indicated that patients with high-risk biochemically recurrent prostate cancer may derive benefit from treatment with androgen deprivation therapy intensification and apalutamide.

Circulating tumor DNA levels could be a potential prognostic tool for predicting outcomes in diffuse large B-cell lymphoma.

Patients with mismatch repair deficient (dMMR) colon cancer experienced a high rate of major pathologic complete response following treatment with nivolumab and ipilimumab for 4 weeks.

In patients with non-germinal center B cell–like diffuse large B-cell lymphoma, the combination of orelabrutinib plus R-CHOP revealed an overall response rate of 86.4%.